Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Trends and Barriers of Medication Treatment for Opioid Use Disorders: A Systematic Review and Meta-Analysis

Published:2023-10-11 Issue: Volume: Page:
ISSN:0022-0426
Container-title:Journal of Drug Issues
language:en
Short-container-title:Journal of Drug Issues

Author:

Hutchison Morica¹^ORCID,Russell Beth S.²,Leander Abigail²,Rickles Nathaniel³,Aguiar Derek⁴,Cong Xiaomei S.⁵,Harel Ofer⁶,Hernandez Adrian V.³⁷

Affiliation:

1. Department of Psychiatry, Center for the Study and Prevention of Suicide, University of Rochester Medical Center, Rochester, NY, USA

2. Human Development and Family Sciences, University of Connecticut, Storrs, CT, USA

3. School of Pharmacy, University of Connecticut, Storrs, CT, USA

4. Computer Science and Engineering, University of Connecticut, Storrs, CT, USA

5. School of Nursing, University of Connecticut, Storrs, CT, USA

6. Department of Statistics, University of Connecticut, Storrs, CT, USA

7. Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola (USIL), Lima, Peru

Abstract

Adherence to and retention in Medication Treatment for Opioid Use Disorders (MOUD) persist. We systematically reviewed trends of USA MOUD adherence, retention, and barriers from 2011–2021. Primary outcomes were adherence to and retention in MOUD, abstinence, adverse events, and treatment barriers. Effects of inverse variance random meta-analyses were examined using proportions and 95% CIs. 28 studies (102,318 patients), 78.1% male. Adherence was 56% across all studies, highest for methadone (73%). Retention by study design was heterogeneous: case series (57%), cohorts (47%), and RCTs (70%). The most common barriers were younger age, comorbid diagnoses, daily attendance, no insurance, and transportation. Abstinence was 72%, and adverse events was 5%. There was high heterogeneity in MOUD across drug types and study designs. Our findings extend the knowledge base of MOUD treatment to describe barriers that underpin the focus on retention in care above adherence given its focus to harm reduction principles.

Funder

the University of Connecticut’s Institute for Collaboration in Health Intervention and Policy (InCHIP).

Publisher

SAGE Publications

Subject

Psychiatry and Mental health,Public Health, Environmental and Occupational Health,Health (social science),Medicine (miscellaneous)

Link

http://journals.sagepub.com/doi/pdf/10.1177/00220426231204841

Reference61 articles.

1. Increased distance was associated with lower daily attendance to an opioid treatment program in Spokane County Washington

2. American Medical Association (AMA) Advocacy Resource Center. (August, 2021). Issue brief: Nation’s drug-related overdose and death epidemic continues to worsen. Updated August 4, 2021, retrieved from: https://www.ama-assn.org/system/files/issue-brief-increases-in-opioid-related-overdose.pdf

3. Spatial access to opioid treatment program and alcohol and cannabis outlets: analysis of missed doses of methadone during the first, second, and third 90 days of treatment

4. The impact of naturalistic cannabis use on self-reported opioid withdrawal

5. Barriers to behavioral health service utilization among first-generation immigrant emerging adults

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. There goes the neighborhood? The public safety enhancing effects of a mobile harm reduction intervention;International Journal of Drug Policy;2024-02

2. Racialized and beneficiary inequities in medication to treat opioid use disorder receipt within the US Military Health System;Drug and Alcohol Dependence;2023-12